Point72 Asset Management
TRDA icon

Point72 Asset Management’s Entrada Therapeutics TRDA Stock Holding History

Point72 Asset Management’s Portfolio TRDA Stock Details TRDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$210K Buy
+28,500
New +$273K ﹤0.01% 3524
2026
Q1 		– Sell
-21,871
Closed -$225K – 4510
2025
Q4 		$225K Buy
+21,871
New +$184K ﹤0.01% 3594
2023
Q2 		– Sell
-2,840
Closed -$41.2K – 2785
2023
Q1 		$41.2K Buy
+2,840
New +$37.9K ﹤0.01% 1821

Other funds holding TRDA

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MC
Merck & Co Rahway, New Jersey $526M AUM 175.27% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
TCG Crossover Management
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
SG
StepStone Group La Jolla, California $2.16B AUM 20.11% 1-Year Est. Return

Point72 Asset Management's TRDA Position: Q2 2026 in Review

Point72 Asset Management opened a new position in Entrada Therapeutics (TRDA) in Q2 2026: 28,500 shares worth $210K. The stake represents ﹤0.01% of the portfolio and ranks #3524 among its holdings. This is a return to the name: Point72 Asset Management previously reported a position in TRDA as recently as Q4 2025.

Point72 Asset Management first reported a position in TRDA in Q1 2023 and has held it in 3 quarters since. The position peaked at $225K in Q4 2025. 128 funds tracked by Wall St. Rank hold TRDA as of Q2 2026.

  • Point72 Asset Management held 28,500 shares of Entrada Therapeutics worth $210K as of Q2 2026.
  • Entrada Therapeutics was a new Point72 Asset Management position in Q2 2026.
  • Entrada Therapeutics made up ﹤0.01% of Point72 Asset Management's portfolio in Q2 2026, its #3524 holding.
  • Point72 Asset Management first reported a position in Entrada Therapeutics in Q1 2023 and has held it in 3 quarters since.
  • Point72 Asset Management's Entrada Therapeutics position peaked at $225K in Q4 2025.
  • 128 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q2 2026.

Based on Point72 Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.